NASDAQ:BIIB

Biogen Stock News

Healthcare > Drug Manufacturers - General

Buy BIIB

*Your capital is at risk

$207.94

+1.66 (+0.80%)

At Close: Aug 07, 2026

Biogen Lifts Profit Estimates. The Stock Rises.

08:40am, Tuesday, 25'th Oct 2022

Biogen raised its earnings per share estimate to $16.50 to $17.15, up from the previously estimated $15.25 to $16.75 range.

Biogen beats revenue expectations in the third quarter

07:36am, Tuesday, 25'th Oct 2022

Biogen's BIIB, +2.62% stock was up 0.7% in premarket trading on Tuesday after it beat expectations for earnings and revenue in the third quarter of the year. The company had earnings of $1.1 billion,

Biogen (BIIB) to Report Q3 Earnings: Here's What to Expect

12:02pm, Friday, 21'st Oct 2022

Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.

This Beaten-Down ETF Is Still a Screaming Bear-Market Buy

05:55am, Friday, 21'st Oct 2022

Investors wanting to profit from a potential biotech sector bounce should love this exchange-traded fund.

Where Will Biogen Be in 5 Years?

10:07am, Thursday, 20'th Oct 2022

Is this biotech an investment worth buying and holding today?

Biogen's (BIIB) FDA Filing for ALS Drug Gets 3 Months Extension

01:33pm, Tuesday, 18'th Oct 2022

The FDA extends the review period for Biogen's (BIIB) NDA for tofersen in SOD1-ALS. This extension is due to BIIB's submission of additional data, constituting a major amendment to the earlier filing.

Biogen's Stock Pullback Offers a Second Chance

02:01am, Tuesday, 18'th Oct 2022

Biogen is positioned to become more diversified over time. A diminishing risk profile combined with emerging growth prospects make the stock attractive.

Biogen: How To Assess Lecanemab's Potential? Invert The Market's Reaction

04:56pm, Monday, 17'th Oct 2022

Lecanemab's successful Phase 3 clinical trial led to Biogen's stock price jumping by 33% in one day. From the reaction to Aduhelm's approval and option chain data, we see that the current stock price

FDA extends review time for Biogen's ALS treatment candidate

08:14am, Monday, 17'th Oct 2022

Shares of Biogen Inc. BIIB, -1.97% gained 1.4% in premarket trading on Monday after telling investors that the Food and Drug Administration extended the review period for its experimental treatment fo

Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity

09:45am, Saturday, 15'th Oct 2022

Let's break down how Biogen makes money right now and what's next for the company in light of some major news that surfaced recently about their new Alzheimer's treatment.

Recession Stocks: Finding Winners In A Down Stock Market

08:45am, Saturday, 15'th Oct 2022

Not all stocks are impacted equally by the economy slowing down. We look at stocks that have been winners during a down stock market thus far in 2022 while most of the rest of the market has fallen.